<DOC>
	<DOCNO>NCT02093598</DOCNO>
	<brief_summary>Type Application : Clinical trial new indication . Experimental drug : The study dose temsirolimus 25 mg administer intravenously , infuse 30- 60-minute period weekly 28 day ( Total dos : 4 dos ) . Temsirolimus selective inhibitor mTOR ( mammalian target rapamycin ) . Pharmacotherapeutic group : Protein Kinase Inhibitors ; ATC code : L01X E09 . Primary Objective : - To identify tumor sample future biomarkers associate short term exposure temsirolimus . - This exploratory clinical study . No efficacy objectives include clinical trial . Secondary Objectives : - To estimate tolerability temsirolimus-treated patient throughout study 28 day last dose temsirolimus . - To correlate observed change different type endometrial carcinoma ( type I type II ) , regard protein relate mTOR ( p4EBP1 , pS6K1 , c-MYC , cyclin D , p27 , BAD , p53 , Bcl-2 PTEN , pAKT , mTOR ) , - To estimate potential predictive value biomarkers ( immunostaining PTEN , pAKT , mTOR ) , relevant mutation PTEN , PI3KCA , k-RAS , CTNNB1 , microsatellite instability status . - To estimate prognostic value Ki67 expression short-term presurgical therapy exposure - To collect data difference expression profile , assess RNA microarrays</brief_summary>
	<brief_title>POEM STUDY : A Phase IIa Trial Endometrial Carcinoma With Temsirolimus</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Endometrioid</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1 . Patients must histologicallyconfirmed endometrial cancer 2 . Stage I II ( grade 1 , 2 3 ) , candidate surgery primary treatment 3 . Age ≥ 18 year 4. WHO performance status ≤ 2 5 . Adequate bone marrow function 6 . Adequate liver function 7 . Adequate renal function 8 . Fasting serum cholesterol ≤300 mg/dL ≤7.75 mmol/L fast triglyceride ≤ 2.5 x ULN 9 . Signed informed consent 1 . Subjects receive prior anticancer therapy current endometrial cancer 2 . Patients , major surgery significant traumatic injury within 4 week start study drug , patient recover side effect major surgery patient may require major surgery course study 3 . Prior treatment investigational drug within precede 4 week 4 . Patients receive chronic , systemic treatment corticosteroid another immunosuppressive agent 5 . Patients receive immunization attenuate live vaccine within one week study entry study period 6 . Uncontrolled brain leptomeningeal metastases 7 . Other malignancy within past 3 year except adequately treat carcinoma cervix basal squamous cell carcinoma skin 8 . Patients severe and/or uncontrolled medical condition condition could affect participation study 9 . Patients active , bleed diathesis 10 . Female patient pregnant breast feeding , adult reproductive potential use effective birth control methods 11 . Patients receive prior treatment mTOR inhibitor 12 . Patients know hypersensitivity rapamycine derivates excipients 13 . History noncompliance medical regimen 14 . Patients unwilling unable comply study protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>pharmacokinetic</keyword>
	<keyword>pharmacodynamic</keyword>
	<keyword>Carcinoma , Endometrioid</keyword>
	<keyword>mTOR protein</keyword>
	<keyword>temsirolimus</keyword>
	<keyword>torisel</keyword>
	<keyword>biological marker</keyword>
	<keyword>phase II</keyword>
</DOC>